IL33 and leukemia: Furthermore, IL-33 treatment significantly improved the efficacy of PD-1 blockade, leading to complete regression of leukemia in half of treated mice, suggesting a viable new combination approach that can be readily translated into the clinic to reverse leukemia-reactive T cell tolerance in promoting leukemia immunotherapy.